|
Name |
Zelkovamycin E
|
Molecular Formula | C35H43N9O9S | |
IUPAC Name* |
(4S,7S,13R,16Z,22R)-7-acetyl-16-ethylidene-4-[(4-methoxy-1H-indol-3-yl)methyl]-7,13,18,22-tetramethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
SMILES |
C/C=C\1/C(=O)N(CC(=O)N[C@@H](C2=NC(=CS2)C(=O)N[C@H](C(=O)N[C@@](C(=O)NCC(=O)N[C@@H](C(=O)N1)C)(C)C(=O)C)CC3=CNC4=C3C(=CC=C4)OC)C)C
|
|
InChI |
InChI=1S/C35H43N9O9S/c1-8-21-33(51)44(6)15-27(47)39-18(3)32-42-24(16-54-32)30(49)41-23(12-20-13-36-22-10-9-11-25(53-7)28(20)22)31(50)43-35(5,19(4)45)34(52)37-14-26(46)38-17(2)29(48)40-21/h8-11,13,16-18,23,36H,12,14-15H2,1-7H3,(H,37,52)(H,38,46)(H,39,47)(H,40,48)(H,41,49)(H,43,50)/b21-8-/t17-,18-,23+,35+/m1/s1
|
|
InChIKey |
JXUQPNLBWOOGRB-HAIQEQOSSA-N
|
|
Synonyms |
Zelkovamycin E
|
|
CAS | NA | |
PubChem CID | 156582957 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 765.8 | ALogp: | 0.3 |
HBD: | 7 | HBA: | 11 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 278.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 54 | QED Weighted: | 0.14 |
Caco-2 Permeability: | -5.806 | MDCK Permeability: | 0.00000426 |
Pgp-inhibitor: | 0.244 | Pgp-substrate: | 1 |
Human Intestinal Absorption (HIA): | 0.651 | 20% Bioavailability (F20%): | 0.986 |
30% Bioavailability (F30%): | 0.993 |
Blood-Brain-Barrier Penetration (BBB): | 0.133 | Plasma Protein Binding (PPB): | 73.04% |
Volume Distribution (VD): | 0.256 | Fu: | 39.83% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.096 |
CYP2C19-inhibitor: | 0.115 | CYP2C19-substrate: | 0.042 |
CYP2C9-inhibitor: | 0.204 | CYP2C9-substrate: | 0.108 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.102 |
CYP3A4-inhibitor: | 0.096 | CYP3A4-substrate: | 0.076 |
Clearance (CL): | 2.39 | Half-life (T1/2): | 0.752 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.697 |
Drug-inuced Liver Injury (DILI): | 0.875 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.03 | Maximum Recommended Daily Dose: | 0.525 |
Skin Sensitization: | 0.108 | Carcinogencity: | 0.012 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.003 |
Respiratory Toxicity: | 0.216 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004435 | 0.840 | D09ZIO | 0.286 | ||||
ENC002016 | 0.822 | D0X9PF | 0.246 | ||||
ENC004432 | 0.801 | D0L7LC | 0.237 | ||||
ENC004433 | 0.714 | D0M2YE | 0.231 | ||||
ENC005139 | 0.333 | D07DSQ | 0.227 | ||||
ENC005343 | 0.302 | D00TLP | 0.227 | ||||
ENC005276 | 0.298 | D02XIY | 0.223 | ||||
ENC002515 | 0.289 | D01XWG | 0.208 | ||||
ENC002514 | 0.281 | D05HPI | 0.207 | ||||
ENC005563 | 0.276 | D0E2OU | 0.205 |